申请人:Pfizer Inc.
公开号:US10323042B2
公开(公告)日:2019-06-18
The present invention is directed to compounds of Formula I:
or a pharmaceutically acceptable salt thereof, wherein the substituents R1, R2, R3, and R4 are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.
本发明涉及式 I 的化合物:
或其药学上可接受的盐,其中取代基 R1、R2、R3 和 R4 如本文所定义。本发明还涉及包含这些化合物的药物组合物、使用这些化合物的治疗方法以及制备这些化合物的方法。